Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

34.20
+1.273.86%
Post-market: 34.200.00000.00%19:30 EDT
Volume:573.47K
Turnover:19.47M
Market Cap:1.04B
PE:-52.28
High:34.70
Open:32.85
Low:32.14
Close:32.93
52wk High:44.28
52wk Low:17.72
Shares:30.55M
Float Shares:28.22M
Volume Ratio:1.54
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6542
EPS(LYR):-0.8334
ROE:-4.20%
ROA:-1.36%
PB:2.22
PE(LYR):-41.03

Loading ...

Castle Biosciences to Present at Baird Global Healthcare Conference

Reuters
·
Aug 20

Castle Biosciences CEO Derek Maetzold Sells USD 203,642 of Common Shares

Reuters
·
Aug 19

Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas

MT Newswires Live
·
Aug 17

Castle Biosciences Approved for Dual Listing on NASDAQ Texas

THOMSON REUTERS
·
Aug 17

Castle Biosciences CEO Derek Maetzold Disposes of 45,016 Common Shares Worth 1.4 Million

Reuters
·
Aug 07

Castle Biosciences CEO Derek Maetzold Reports Disposal of Common Shares Valued at $791,790.26

Reuters
·
Aug 05

Castle Biosciences is Maintained at Buy by BTIG

Dow Jones
·
Aug 03

Castle Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Earnings Flash (CSTL) Castle Biosciences Posts Q2 Adjusted EPS -$0.07, vs. FactSet Est of -$0.41

MT Newswires Live
·
Jul 31

Castle Biosciences reports Q2 EPS (7c), consensus (41c)

TIPRANKS
·
Jul 31

Castle Biosciences Q2 FY26 Net Loss Widens to $2.1 Million; Revenue Rises 20.1% to $103.5 Million

Reuters
·
Jul 31

Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate

Benzinga Earnings
·
Jul 31

Castle Biosciences - Raises Fy2026 Revenue Guidance to $365-$375 Mln

THOMSON REUTERS
·
Jul 31

Castle Biosciences - Expects Positive Adj Ebitda for Q3, Q4, and Fy2026

THOMSON REUTERS
·
Jul 31

Castle Biosciences CEO Derek Maetzold Disposes of $202,507 in Common Shares

Reuters
·
Jul 30

SciBase CEO Pia Renaudin to Step Down as Board Launches Successor Search

Reuters
·
Jul 28

Castle Biosciences CEO Derek J. Maetzold Disposes of 550 Common Shares Worth $12,606‬‬

Reuters
·
Jul 17

Castle Biosciences Gets New York State Department of Health Approval of AdvanceAD-Tx Test

MT Newswires Live
·
Jul 15

Castle Biosciences Announces New York State Department of Health Approval of Its Advancead-tx™ Test

THOMSON REUTERS
·
Jul 15

Castle Biosciences Schedules Second-quarter Results Webcast

Reuters
·
Jul 09